Virtual ACC 2020 | PRECOMBAT: 10 Years for Surgery vs. Angioplasty in Left Main Coronary Artery Disease

After 10 years of follow-up, there were no significant differences in the rates of major adverse cardiovascular or cerebrovascular events among patients with left main coronary artery disease randomized to angioplasty or surgery. Since this was the first study to randomize patients with left main coronary artery disease to angioplasty or surgery, it enrolled very few patients. As a consequence, it lacks the statistical power to generate definitive conclusions.

The PRECOMBAT (Premier of Randomized Comparison of Bypass Surgery versus Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease) study randomized 300 patients to angioplasty with a sirolimus-eluting stent and another 300 patients to surgery, to treat left main coronary artery disease in 13 Korean hospitals between 2004 and 2009.

The follow-up was extended to 10 years for all patients, with a mean of 11.3.

After this incredibly long period, the primary composite endpoint of death, infarction, stroke, or target vessel revascularization occurred in 29.8% of patients in the angioplasty arm and 24.7% of patients in the surgery arm (hazard ratio [HR]: 1.25; 95% confidence interval [CI]: 0.93-1.69).


Read also: Virtual ACC 2020 | Controversial Trial ISCHEMIA Finally in NEJM.


The outcomes are practically identical between strategies once revascularization is excluded (18.2% vs. 17.5%; HR: 1.00; 95% CI: 0.70 to 1.44).

All-cause death rates were also quite similar (14.5% vs. 13.8%).

The only variable differentiating both strategies at 10 years is, as expected, target vessel revascularization (16.1% vs. 8.0%).

Conclusion

The 10-year follow-up of pioneer study PRECOMBAT shows us similar rates of major adverse cardiovascular or cerebrovascular events among patients with left main coronary artery lesions randomized to angioplasty or surgery.

precombat-10-anos

Original Title: Ten-Year Outcomes After Drug-Eluting Stents Versus Coronary Artery Bypass Grafting for Left Main Coronary Disease. Extended Follow-Up of the PRECOMBAT Trial.

Reference: Duk-Woo Park et al. Circulation 2020; Epub ahead of print y presentado en forma virtual en el ACC 2020.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

CRABBIS Trial: Comparison of Different Provisional Stenting Sequences

Provisional stenting (PS) is the gold standard for percutaneous coronary intervention (PCI) in most patients with coronary bifurcation lesions (CBL). Moreover, recent studies such...

Andromeda Trial: Meta-Analysis of Drug Coated Balloon vs. DES in Small Vessel DeNovo Lesions

The use of coronary stents vs plain old balloon angioplasty (POBA), has allowed to reduce recoil and limiting flow dissection which were major limitation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...